Skip to content
Review

Cortisol in cardio-kidney-metabolic disease.

Oct 2026 · European Heart Journal · 0 citations · 84 references
Medicine

TL;DR

The epidemiology and mechanisms linking cortisol excess to CKM dysfunction are summarized, and the need for clinical trials, standardized diagnostic thresholds, and assays to enable integration of cortisol-targeted therapies into management pathways to mitigate residual CKM risk is highlighted.

Abstract

Despite guideline-directed therapy, many patients with cardio-kidney-metabolic (CKM) disease remain uncontrolled due to therapeutic inertia, adherence barriers, and underrecognized secondary causes. Hypercortisolism, ranging from mild autonomous cortisol secretion (MACS) to overt Cushing syndrome, is an increasingly recognized contributor. MACS is associated with a 2.5-fold higher risk of cardiovascular death and increased prevalence of hypertension, type 2 diabetes mellitus (T2DM), and kidney impairment. Cortisol excess promotes muscle insulin resistance, hepatic gluconeogenesis, β-cell dysfunction, sodium retention, and vascular remodelling, worsening glycaemia and blood pressure, leading to poor CKM outcomes. Recent prospective studies suggest that hypercortisolism is more prevalent than previously suspected in selected CKM phenotypes, including 24% in patients with difficult-to-control T2DM in CATALYST and 27% in patients with resistant hypertension in MOMENTUM. The overnight 1 mg dexamethasone suppression test remains the diagnostic test of choice. Therapeutic strategies include adrenal steroidogenesis inhibitors, glucocorticoid receptor antagonists, and pituitary-directed therapies in selected cases, while surgery remains the first-line treatment for surgically remediable disease. This review summarizes the epidemiology and mechanisms linking cortisol excess to CKM dysfunction, and also highlights the need for clinical trials, standardized diagnostic thresholds, and assays to enable integration of cortisol-targeted therapies into management pathways to mitigate residual CKM risk. This review will serve as a practical guide for cardiologists to manage a potentially reversible contributor to poor CKM control.

View source

Similar papers

Open access Sep 2026

Iatrogenic hypercalcemia in a patient with type 2 diabetes and chronic kidney disease

A 59-year-old man with obesity, type 2 diabetes, CKD stage 3b, albuminuria and established cardiovascular disease receiving optimized treatment with renin–angiotensin–aldosterone system blockade, sodium-glucose cotransporter-2 inhibition, semaglutide and finerenone develops symptomatic severe non-parathyroid hormone-me...

M. Mačković, N. Marić, I. Kralj et al. · 0 citations
Open access Oct 2026

Reduced Risk of MASLD and Cardiometabolic Disease Following Renal Denervation Therapy in Patients With Resistant Hypertension.

INTRODUCTION Autonomic dysfunction increases the risk of cardio-kidney-metabolic (CKM) syndrome including metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD). Renal denervation reduces renal sympathetic nerve activity and...

A. Henney, M. Anson, David R. Riley et al. · 0 citations
Review Open access Nov 2026

Before the storm: insulin resistance as a sentinel biomarker across the cardiometabolic continuum. A comprehensive narrative review

Insulin resistance (IR) is often seen as a curiosity associated with prediabetes and polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS). However, it is a significant early indicator of progression towards type 2 diabetes, cardiovascular disease, heart failure, chronic kidney disease, and liver disease. This...

A. García, J. D. de Sanctis, Gerardo Antonio Celli Kubler · 0 citations
Review Open access Sep 2026

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.

Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as an additional pillar of cardiorenal therapy alongside...

E. Pedagogos, Roger Chen, Adam J. Nelson et al. · 0 citations
Review Oct 2026

Potassium and Cardiovascular Disease.

Hyperkalemia (potassium levels >5.5 mEq/L) or hypokalemia (potassium < 3.5 mEq/L) may incur potentially serious cardiovascular (CV) complications. Hyperkalemia is most commonly encountered in renal failure, K+ oversupplementation for diuretic therapy, use of potassium-sparing diuretics, therapy with angiotensin-convert...

A. Manolis, Theodora A. Manolis, A. Vouliotis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.